Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05933174 · ClinicalTrials.gov registry record · NA
Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes
A NA study of Type 2 Diabetes, sponsored by Ian J. Neeland, MD.
- Recruiting
- Registry status
- NA
- Development phase
- 220
- Enrollment target
- 1
- Study location
NCT05933174: Recruiting NA study of Type 2 Diabetes, sponsored by Ian J. Neeland, MD.
NCT05933174 is a NA study of Type 2 Diabetes that is actively recruiting participants, run by Ian J. Neeland, MD. The registered enrollment target is 220 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05933174, a NA study of Type 2 Diabetes, is actively recruiting participants, sponsored by Ian J. Neeland, MD.
- RECRUITING
- Registry status
- NA
- Development phase
- 220 participants
- Enrollment target
- 1
- Study location
Study Summary
Sulfonylurea medications are unsafe for older patients with diabetes. They are associated not only with hypoglycemia, but also with falls and increased cardiovascular risk. Yet they continue to be prescribed frequently. Indeed, older adults with type 2 diabetes, who are especially prone to adverse effects, are more likely to be prescribed sulfonylureas than younger patients. This is unfortunate since over the past several years, newer, safer, and more effective classes of medications (GLP-1 agonists and SGLT2-inhibitors) have emerged. The investigators acknowledge that sulfonylureas are inexpensive and that their low cost is a driver of continued use. However, the investigators believe patients and providers should have discussions about the risks of sulfonylureas and safer and more effective alternatives, to make diabetes care safer overall in ambulatory settings. Our research is designed to promote such discussions. The investigators will first identify patients taking sulfonylureas regularly. Next, using recommendations from AHRQ and the Canadian Deprescribing Network, the investigators will empower patients to discuss their medications with their providers through a simple question prompt sheet. Patients will be divided into an intervention group which receives explicit prompting questions, and a control group that receives a general brochure on diabetes medications. Health care providers will receive education about newer diabetes medications through case-based discussions and academic detailing. Finally the investigators will measure key outcomes including the proportion of patients who have discussions about sulfonylureas and alternatives, rates of discontinuation, and measures of control of diabetes and associated cardiovascular risks. The investigators will also evaluate the experiences of patients and providers qualitatively through brief, semi-structured interviews. Should our multi-faceted, patient-oriented intervention prove effective in promoting discu
Primary Outcome
Proportion of patients who had a conversation with their primary care provider about SU use and alternatives for their diabetes management
Conditions Studied
Interventions
- OTHER Prompt-sheet
- OTHER Usual education
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2023-10-01 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What NCT05933174 shows while recruiting
NCT05933174 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Prompt-sheet is the first listed.
NCT05933174 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05933174 about?
NCT05933174 is a clinical study titled "Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes". Sulfonylurea medications are unsafe for older patients with diabetes. They are associated not only with hypoglycemia, but also with falls and increased cardiovascular risk. Yet they continue to be prescribed frequently. Indeed, older adults with type 2 diabetes, who are especially prone to adverse e...
What is the current status of trial NCT05933174?
This trial is currently recruiting. It is a NA study. The enrollment target is 220 participants. The study started on 2023-10-01. Estimated completion is 2026-06-30.
What conditions does trial NCT05933174 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT05933174?
The interventions under investigation include: Prompt-sheet (OTHER), Usual education (OTHER).
Who is sponsoring clinical trial NCT05933174?
This trial is sponsored by Ian J. Neeland, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05933174 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05933174's enrollment target sits among peer trials
220 89th of 327 higher than 239 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI